It's your patient's
MDD story
Is it time to help write her next chapter?
TRINTELLIX® (vortioxetine) is indicated for the treatment of Major Depressive Disorder (MDD) in adults.
Patient portrayal.
Individual results may vary.
It's your patient's
MDD story
Is it time to help write her next chapter?
Patient portrayal.
Individual results may vary.
Based on MADRS or HAM-D24 total scores,
as shown in 6 short-term (6- to 8-week) MDD studies and 2 long-term (24- to 64-week) MDD studies.1
Abbreviations: HAM-D24, Hamilton Depression 24-item Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; MMRM, mixed model repeated measures.
TRINTELLIX has been prescribed to nearly
2 million patients in the US.10
Support for
your patients
We’re here to help your eligible patients get the treatment you prescribe.
Long-term
clinical data
Results from multiple clinical studies of TRINTELLIX.
Offering
patients once
daily dosing
Learning about dosage amounts and drug interactions.
Telling patients
about telehealth
As telehealth visits become more common, it’s important to have helpful resources for you and your patient.
Patient profile
Learn more about a patient
living with MDD.
Safety profile
See how the safety profile fits in the story.
Helping patients
access savings
info and support
Discover resources that may help your patients with savings and more.
Prescription
savings for your
eligible patients
Find out about savings and support offered through tAccess by reading the Savings Card brochure.
Request a
rep visit
Connect with a TRINTELLIX representative.
Patient coverage
in your area
Find out about formulary coverage in your area for TRINTELLIX.
Leaving TRINTELLIXHCP.COM
By clicking “Continue,” you will be leaving a Takeda and Lundbeck controlled website for a third-party website.
Please note that neither Takeda nor Lundbeck is responsible or liable for any third-party website, and the website may not be appropriate for all audiences.